RHYTHM PHARMACEUTICALS, INC. — Director's Dealing 2024

Sep 11, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK: 0001649904
Period of Report: 2024-09-09

Reporting Person: Cramer Pamela J. (Chief Human Resources Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-09-09	Common Stock	M	4099	$19.02	Acquired	17599	Direct
2024-09-09	Common Stock	S	4099	$50.0274	Disposed	13500	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-09-09	Stock Options (Right to buy)	$19.02	M	4099	Disposed	2031-07-25	Common Stock (4099)	Direct

Footnotes

F1: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted on May 10, 2024.

F2: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $50.00 to $50.13. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

F3: The stock options were granted on July 26, 2021. 25% of the shares subject to the option vested and became exercisable on July 26, 2022 and the remaining 75% of the shares subject to the option vest or have vested and become exercisable in 12 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer thereafter.